Remote Electrical Neuromodulation Reported As Viable Alternative to Drugs for Acute Migraine

Published in Frontiers in Neurology

Remote Electrical Neuromodulation:

Theranica Bioelectronics (Theranica), is a bio-medical technology company developing advanced electroceuticals for migraine and other pain conditions.  Today the company announced that Frontiers In Neurology Journal published an article demonstrating that incorporating Remote Electrical Neuromodulation (REN) treatment into usual care of migraine has the potential to reduce reliance on acute pharmacological medications.

“This study signals a potentially significant shift in how we approach the acute treatment of migraine,” said lead author Michael Marmura, MD, Headache Specialist at the Thomas Jefferson University Hospital in Philadelphia. “Adding REN as an alternative to traditional migraine treatments opens the door to new long-term treatment strategies. What is most promising is the fact that so many patients in the study chose REN without being specifically prompted, and experienced treatment outcomes similar or slightly better than their usual care.”

In a cohort of 117 patients who were given the option of using REN in addition to or instead of their usual care treatments, such as triptans or over-the-counter (OTC) medications, 89.7% used REN exclusively, without medications. When REN was not available, only 15.4% chose to avoid medications in all their reported migraine attacks. The patients who used REN exclusively reported similar treatment outcomes to their usual (pharmacological) care. The article concludes that “Incorporating REN into usual care may have a positive impact on migraine management by reducing the reliance on acute medications.”

“When patients experience debilitating migraine symptoms, they are looking for effective relief,” said Dr. Morris Levin, chief of the headache medicine division and director of the Headache Center at UCSF Medical Center in San Francisco, who served as the chairman of the independent Data and Safety Monitoring Committee of the study. “Traditionally we’ve had only a limited number of useful acute migraine treatments, many of which have side effects. REN is a welcome option, due to its apparent safety and almost nonexistent adverse effects.  In addition, the risk of medication overuse, often a limiting factor with acute medications, should not be an issue when using a drug free therapy such as REN.”

The device used in the study was Theranica’s FDA-authorized prescribed therapeutic wearable, Nerivio. The device deploys REN to activate the body’s native Conditioned Pain Modulation (CPM) mechanism to treat pain and accompanying migraine symptoms. Nerivio, which was recently named one of TIME’s best inventions of 2019, is available in the US with a valid prescription. It is also accessible via online telemedicine portals Cove or UpScript, which provide physician consultations and home delivery.


Other device industry news items can be found here.

Medical Device News Magazinehttps://infomeddnews.com
Our publication is dedicated to bringing our readers the latest medical device news. We are proud to boast that our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall purpose and objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

Data from clinical studies of STK-001 demonstrated clinical benefit for patients ages 2 to 18 years old, including reductions in seizures and improvements in cognition and behavior that support the potential for disease modificatio. Analysis of 72 patients treated in STK-001 clinical trials suggests that higher STK-001 drug exposure in brain leads to greater seizure reductions. Two-year data from the longest prospective natural history study of Dravet syndrome showed that, on average, patients experienced no meaningful improvement in convulsive seizure frequency and exhibited widening gaps in cognition and behavior despite treatment with the best available anti-seizure medicines.
"Exact Sciences is looking forward to presenting new evidence at SABCS that adds important perspectives to treating breast cancer patients and showing that some patients may be able to de-escalate treatments and still have positive outcomes," said Dr. Rick Baehner, Chief Medical Officer, Precision Oncology, Exact Sciences. "Every year, we build upon the precedent set by the Oncotype DX Breast Recurrence Score® test and its prognostic and predictive abilities to determine the chemotherapy benefit for specific breast cancer patients. We are pleased to see authorities expanding access to this test as we continue to develop key evidence in collaboration with some of the world's most prestigious, breast cancer-focused organizations."
Clozapine has been established as the most effective antipsychotic medication for treatment-resistant schizophrenia. However, it is significantly underutilized mainly due to the risk of developing agranulocytosis and the need to frequently monitor the absolute neutrophil count (ANC).
Dagi-Ben Noon, CEO of Inspira Technologies, reflects on the partnership's significance: "By Integrating our technology to oxygenate blood directly with Ennocure's infection prevention solutions, we are focusing on potentially improving patient outcomes in ICUs and paving the way for safer, more effective life-support treatments. This collaboration is expected to accelerate the development and broaden the implementation of our advanced technology."
The findings suggest that the novel, non-invasive genomic test can help physicians guide next steps for these patients, enabling them to potentially avoid unnecessary invasive procedures or accelerate time to appropriate treatment.

By using this website you agree to accept Medical Device News Magazine Privacy Policy